A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Formulary Watch
Latest News
All News
Advertisement
The Amgen Biosimilars Trend Report found that competition is lowering prices of biosimilars but the largest PBMs are inconsistent in their management of these products.
Exela has received five reports of flying glass injuring skin, eye and/or other parts. The recall includes both Exela and Civica brands.
Until supply is restored, the FDA suggests the use of alternatives such as the extended-release version of amphetamine mixed salts.
Regence implemented a preferred infliximab biosimilar strategy and was able to achieve more than 90% adoption.
If approved, valoctocogene roxaparvovec would be the first gene therapy in the U.S. for the treatment of severe hemophilia A. A PDUFA action date has been set for March 31, 2023.
The bivalent booster vaccines add the omicron variant BA.4 and BA.5 to the original SARS-CoV-2 along with a component of omicron BA.1.
In total, CVS Caremark has removed 26 products and added 31 products effective Jan. 1, 2023.
The FDA has assigned a target action date of Feb. 11, 2023.
The submission is expected to be complete by the end of the year, and if approved, could be available in early 2024.
Advertisement
The FDA is asking for additional analysis related to the infusion device used with SPN-830, which contains apomorphine to treat patients with Parkinson’s disease.
Furoscix can be administered at home with the use of the On-Body Infusor, which delivers furosemide over five hours. It will be launched in the first quarter of 2023.
Ashley Jenne, managing director, strategy and business development at Evernorth, discusses the evolution of the PBM’s digital health formulary.
Regulators used a re-analysis of data from an observational case-control study of Tdap vaccine effectiveness to show that Boostrix given in the third-trimester prevented pertussis among infants.
This approval for Oxlumo adds lowering plasma oxalate levels for patients with primary hyperoxaluria type 1, a rare and life-threatening metabolic disease.
In 2023, Capital Blue Cross members will be able to use their insurance cards at Mark Cuban Cost Plus Drugs. This is the first time the online pharmacy will accept insurance.
EmpiRx Health CEO Karthik Ganesh discusses how the PBM was able to decrease mental health drug spending at a time when utilization is increasing.
The FDA had indicated that it would not issue an emergency use authorization without additional data for peginterferon lambda to treat patients with mild-to-moderate COVID-19.
UnitedHealthcare is moving more drugs to the lower-cost tiers in its Medicare Advantage plans. Other plans will have $0 copays and insulin at a $25 copay.
The FDA is expected to make a decision on approval in this patient population in the first half of 2023.
Medicare and Medicaid spent more than $18 billion on drugs without verified clinical benefit.
The online pharmacy has added 12 new products and lowered the costs of 39 medications.
SIGA indicated that $5.1 million of oral Tpoxx is targeted for delivery in 2022.
All plans have $0 copay options for select medications purchased through preferred home delivery.
In one lot, a bottle containing clopidogrel was mislabeled as atenolol. This lot was sold to AmerisourceBergen and McKesson.
Trogarzo was approved with a new method of administration designed to make maintenance dosing easier for patients and healthcare providers.
Advertisement
Advertisement